Abstract

Dinucleotide analogs of the messenger RNA cap (m7GpppN) are useful research tools and have potential applications as translational inhibitors or reagents for modification of in vitro transcribed mRNAs. It has been previously reported that replacing the methyl group at the N7-position with benzyl (Bn) produces a dinucleotide cap with superior properties. Here, we followed up on this finding by synthesizing 17 novel Bn7GpppG analogs and determining their structure–activity relationship regarding translation and translational inhibition. The compounds were prepared in two steps, including selective N7-alkylation of guanosine 5′-monophosphate by arylmethyl bromide followed by coupling with imidazole-activated GDP, with total yields varying from 22% to 62%. The compounds were then evaluated by determining their affinity for eukaryotic translation initiation factor 4E (eIF4E), testing their susceptibility to decapping pyrophosphatase, DcpS—which is most likely the major cellular enzyme targeting this type of compound—and determining their translation inhibitory properties in vitro. We also synthesized mRNAs capped with the evaluated compounds and tested their translational properties in A549 cells. Our studies identified N7-(4-halogenbenzyl) substituents as promising modifications in the contexts of either mRNA translation or translational inhibition. Finally, to gain more insight into the consequences at the molecular level of N7-benzylation of the mRNA cap, we determined the crystal structures of three compounds with eIF4E.

Highlights

  • Eukaryotic mRNAs carry at their 50 ends a protective cap

  • Comparing the binding constant values KD of compound 1a with the native cap structure (m7 GpppG), we found that replacing the methyl group at the N7 position of guanosine slightly stabilized the complex with eukaryotic translation initiation factor 4E (eIF4E), which is in agreement with previous findings (Table 1) [11]

  • After determining the affinity for eIF4E and susceptibility to decapping pyrophosphatase (DcpS), we evaluated the analogs as inhibitors of protein translation in rabbit reticulocyte lysates (RRL)

Read more

Summary

Introduction

Eukaryotic mRNAs carry at their 50 ends a protective cap. The 7-methylguanosine cap can only be removed from the mRNA 50 end by specialized decapping enzymes, and as such, protects mRNA from premature degradation by 50 exonucleases. Chemical modifications of the 50 cap have the potential to modulate the properties of the whole mRNA, including its stability and translational efficiency. MRNAs modified within the 50 cap can be obtained by incorporating chemically synthesized dinucleotide cap analogs into mRNA during. Pharmaceutics 2021, 13, 1941 in vitro transcription (so-called co-transcriptional capping) [4,5,6]. Modifications conferring superior biological properties to mRNAs are interesting objects for biological studies, but may advance the use of mRNA as a therapeutic modality [7,8,9]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call